7 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 7 of 7 clinical reviews.
A detailed review of isotretinoin (Accutane) safety signals reported to the FDA Adverse Event Reporting System (FAERS), covering psychiatric events, IBD associations, teratogenicity monitoring through iPLEDGE, and what the post-market surveillance data mean for prescribers and patients.
Complete regulatory timeline of isotretinoin from its 1982 FDA approval through iPLEDGE implementation, generic entry, and ongoing post-market safety surveillance.
Current isotretinoin regulatory status in the United States, European Union, United Kingdom, Canada, Australia, and Brazil, including iPLEDGE and pregnancy-prevention rules.
A complete clinical reference covering every FDA label change, iPLEDGE revision, and post-market safety signal for isotretinoin from 2020 through 2026, with primary-source citations throughout.
A clinical review of isotretinoin's regulatory history, current FDA label requirements, iPLEDGE program updates, next-generation retinoid pipeline candidates, and post-market safety surveillance data.
Isotretinoin cannot be legally compounded under 503A or 503B rules. iPLEDGE and Category X teratogenicity make compounded Accutane prohibited and unnecessary.
Accutane was withdrawn in 2009 after IBD lawsuits; generic isotretinoin still sold under the iPLEDGE REMS program. Full legal and patent timeline inside.